The future of preventative medicine starts with Precure Genomic screening.

Precure Genomic screening: Why preventative genetic testing is becoming a cornerstone of modern healthcare

Study reveals that 1 in 8 apparently healthy adults unknowingly carries a serious genetic risk

Precure Genomic screening is emerging as a powerful preventative health tool that can identify serious inherited disease risks years before symptoms appear.

A growing body of evidence shows that many people who consider themselves healthy carry clinically significant genetic variants associated with conditions such as hereditary cancers, heart disease and other potentially life-threatening disorders.

A landmark Mayo Clinic study published in Genetics in Medicine found that approximately 13% of apparently healthy adults had actionable genomic findings that traditional symptom-based healthcare would likely miss.

This article explains why preventative genomic screening is gaining attention worldwide, how the Precure initiative is designed to detect disease earlier, and why integrating genetic information into routine medical care could transform long-term health outcomes. It also examines the practical challenges of turning genetic discoveries into effective clinical action.

Key Takeaways

About 1 in 8 healthy adults may carry a serious actionable genetic risk.
Traditional screening based only on symptoms can miss inherited disease risk.
Precure Genomic screening combines genomic data with AI-enabled disease prediction.
Early identification can enable monitoring, prevention and earlier treatment.

The shift from reactive medicine to preventative genomics

For most of modern medical history, healthcare has been largely reactive. Patients developed symptoms, sought medical attention and then underwent testing to determine the cause. This approach has produced extraordinary advances in treatment, but it often identifies disease only after biological damage has already begun.

Genomic medicine is changing that model. By analysing an individual’s DNA before illness develops, clinicians can identify inherited risks that may increase the likelihood of cancer, cardiovascular disease, metabolic disorders and other serious conditions. The goal is not to predict the future with certainty. Instead, it is to recognise elevated risk early enough for monitoring, lifestyle interventions or targeted medical care to reduce the chance of severe disease.

This preventative approach is becoming increasingly important as genomic sequencing becomes faster, more accurate and more affordable. The concept behind Precure Genomic screening is that disease often leaves detectable biological signals long before symptoms appear. Identifying those signals may allow healthcare systems to intervene earlier and more effectively.

The Mayo Clinic study that changed the conversation

The urgency of preventative genomic screening became clearer through a major Mayo Clinic research project involving adults who appeared healthy and had no obvious indication for genetic testing.

According to the study: “When Mayo Clinic researchers sequenced the genomes of 484 seemingly healthy adults, they found that about 13% carried a serious, previously unrecognized genomic risk — conditions those patients did not know about and that standard care would likely miss.”

The findings were striking. Nearly every participant had at least one genetic finding that warranted some degree of medical awareness or monitoring. More importantly, approximately one in eight participants carried what researchers classified as actionable genetic variants.

Those variants were associated with conditions including hereditary breast and ovarian cancer, Lynch syndrome, cardiomyopathy, long QT syndrome and amyloidosis. Many of these disorders can remain silent for years before causing serious illness.

The study demonstrated that relying solely on symptoms or family history may leave a substantial number of at-risk individuals unidentified.

Why family history alone is not enough

For decades, physicians have used family history as a primary tool for deciding who should receive genetic testing. While family history remains valuable, it has important limitations.

Some people are adopted and do not know their biological relatives. Others come from small families where inherited conditions have not yet appeared. In some cases, relatives may have died before receiving an accurate diagnosis. Genetic risk can also be inherited from a parent who never developed the disease despite carrying the same variant.

That is why the Mayo Clinic researchers emphasised the importance of population-based genomic screening rather than testing only those with obvious clinical clues.

“These are people traditional testing based on symptoms or family history would not identify,” says Dr Konstantinos Lazaridis, the Carlson and Nelson Endowed Executive Director of the Center for Individualized Medicine and senior author of the study. “This study helps define the blueprint for integrating genomic insight into care at scale turning information into decisions that can change the trajectory of disease.”

This statement captures a central idea in preventative genomic medicine: the value of genetic information lies not merely in discovering a variant, but in using that knowledge to guide real healthcare decisions.

What happens during Precure Genomic screening?

Genomic screening is often less complicated than many people imagine. The process usually begins with a blood sample or saliva sample. DNA is extracted and sequenced using advanced laboratory technology capable of reading millions of genetic markers across the genome.

Specialised bioinformatics systems then compare an individual’s genetic data with large databases of known disease-associated variants. The analysis focuses on variants that have strong scientific evidence linking them to clinically important conditions.

Results are not interpreted by computers alone. Clinical geneticists and genetic counsellors review the findings to determine whether a variant is truly actionable and what follow-up care may be appropriate.

In the Mayo Clinic study, this interpretation process proved to be one of the most important parts of the entire programme.

The essential role of genetic counsellors

One of the most revealing aspects of the study was that identifying a genetic variant was only the beginning. Helping patients understand and act on the information required extensive clinical support.

The researchers found that nearly every actionable result required interpretation, documentation and communication with patients and healthcare teams.

“Genetic counselors are often the first people to share this kind of information with patients,” says Jessa Bidwell, a certified research genetic counselor and first author of the study. “There can be surprise, anxiety, devastation, and at times relief at finally having an explanation. Our role is to meet people in that moment and help them understand what their health risks might be, based on the genetic finding, and their personal and family history.”

This highlights an important misconception about preventative genetic testing. Genomic screening is not simply a laboratory test. It is a clinical process that combines sequencing technology, medical interpretation and patient counselling.

Without that support, individuals may struggle to understand whether a finding represents a minor concern, a significant risk or a result requiring immediate medical attention.

Early detection can change outcomes

The greatest potential benefit of preventative genomic screening is the opportunity to intervene before disease becomes advanced.

Consider hereditary breast and ovarian cancer associated with certain BRCA variants. Individuals who know they carry these variants can begin enhanced surveillance earlier than the general population. Similar strategies exist for Lynch syndrome, where earlier and more frequent colorectal screening can identify precancerous changes before cancer develops.

For inherited cardiac conditions such as long QT syndrome or cardiomyopathy, genomic screening may lead to cardiac monitoring, medication adjustments or lifestyle recommendations that reduce the risk of dangerous arrhythmias or heart failure.

In many cases, the goal is not to eliminate risk entirely. The goal is to move from unexpected crisis to informed prevention.

The Mayo Clinic study found that most participants who received actionable results did follow through with referrals and specialist evaluations. That suggests many people are willing to act when given clear, clinically meaningful information.

Precure Genomic screening and the future of predictive healthcare

The Mayo Clinic study makes it clear that identifying hidden genetic risk is only the first step in transforming healthcare. The larger challenge is building a healthcare system capable of using genomic information consistently, efficiently and equitably. A genetic result has little value if it remains isolated in a laboratory report. It becomes clinically meaningful only when physicians, genetic counsellors, specialists and patients work together to convert that information into an evidence-based prevention strategy.

The researchers recognised this distinction throughout their work. While most participants with actionable findings completed referrals and connected with specialists, fewer than half had a documented conversation with their primary care professional after receiving their results. This gap illustrates one of the greatest obstacles facing genomic medicine today. Sequencing technology has advanced rapidly, yet healthcare delivery systems continue adapting to incorporate genomic information into routine clinical practice.

Rather than viewing this as a limitation, the study presents it as an opportunity to redesign healthcare around earlier intervention instead of later treatment. As genomic testing becomes increasingly accessible, healthcare providers will require new clinical pathways, improved education and greater collaboration between primary care physicians, specialists, genetic counsellors and laboratory scientists.

Precure Genomic screening aims to detect disease before symptoms appear

The Mayo Clinic initiative known as Precure represents one of the most ambitious efforts to redefine preventative medicine through genomic science and advanced computing.

“Most diseases don’t arrive without warning. They begin with small shifts in genes, molecules, proteins and immune signals that develop over time, often years before symptoms appear.”

This concept reflects a growing scientific understanding that many chronic illnesses develop silently over decades. Alzheimer’s disease, cardiovascular disease, chronic kidney disease and several cancers frequently begin with microscopic biological changes that are invisible during routine clinical examinations. By the time symptoms develop, irreversible tissue damage may already have occurred.

Rather than waiting for illness to become clinically obvious, Precure seeks to identify those biological warning signs while intervention remains most effective.

The initiative extends beyond genetics alone. Modern disease prediction increasingly combines genomic information with proteomics, metabolomics, immune profiling, medical imaging, electronic health records and longitudinal clinical data. Together, these diverse sources create a far more comprehensive picture of an individual’s health trajectory than any single laboratory test could provide.

Your ultimate All-In-One indoor fitness solution

Speediance gym Monster 2, smart strength training equipment at home. With digital weight adjustment, compact design, and AI-powered training system.

Artificial intelligence is accelerating genomic medicine

The enormous quantity of information generated by whole genome sequencing exceeds the capacity of traditional medical analysis. Each human genome contains approximately three billion DNA base pairs and millions of genetic variations. Determining which of those variations are clinically significant requires computational methods that continue to improve with advances in artificial intelligence.

“Precure is Mayo Clinic’s enterprise-wide effort to detect those early signals and intervene sooner. Powered by advanced computing and artificial intelligence (AI), the initiative currently focuses on five organ systems the brain, heart, kidneys, liver and lungs studying conditions such as Alzheimer’s disease, heart failure and chronic liver disease to better understand how they emerge and progress.”

Artificial intelligence enables researchers to detect subtle relationships between genetic variants, biomarkers, medical histories and disease outcomes that would be difficult or impossible for humans to recognise unaided. Machine learning models continually improve as additional patient data become available, allowing prediction algorithms to become increasingly accurate over time.

Importantly, AI does not replace physicians. Instead, it functions as a sophisticated analytical tool that helps clinicians interpret extraordinarily complex biological information while supporting evidence-based decision making.

Precision medicine is becoming preventative medicine

Traditional healthcare often applies standard recommendations across broad populations. Precision medicine seeks to individualise healthcare according to each person’s unique biological characteristics.

Preventative genomic screening represents one of the clearest examples of this approach.

Two individuals may appear equally healthy during a routine medical examination, yet their inherited genetic risks could differ dramatically. One may carry pathogenic variants associated with aggressive hereditary cancer syndromes, while the other has no known inherited predisposition. Their future screening schedules, preventative interventions and long-term medical monitoring may therefore differ substantially.

This represents a fundamental evolution in medicine. Instead of treating everyone identically until disease develops, clinicians can increasingly tailor prevention according to measurable biological risk.

For patients, this may translate into earlier cancer surveillance, more frequent cardiovascular monitoring, targeted imaging, specialised laboratory testing or preventative medications when supported by established clinical guidelines.

K-Swiss Men’s Tubes 200 Training Shoe

PATENTED TUBES TECHNOLOGY: The technology provides unmatched comfort and cushioning through individually tuned tube structures that collapse and rebound as you walk. The design also provides incredible flexibility making every stride smooth and efficient. Smaller, more rigid tubes on the inside area of the heel provide extra medial support to reduce pronation
TEXTILE UPPER: Lightweight mesh upper provides additional coolness and breathability
CMEVA MIDSOLE: Compression moulded EVA midsole provides optimal lightweight cushioning
ORTHOLITE SOCK LINER: The unique open-cell structure of OrthoLite foam creates a moisture management system, helping to move moisture away and provide a cooler, drier, healthier environment
COMFORT: Padded collar and tongue for snug fit and extra comfort

Ethical considerations remain central

Despite its promise, preventative genomic screening raises important ethical, legal and social questions that healthcare systems must address carefully.

Genetic information is among the most personal forms of medical data. Patients must understand what testing can reveal, how results will be interpreted, who will have access to the information and how incidental findings may affect family members.

Some individuals experience reassurance after learning their genetic status, while others may experience understandable anxiety upon discovering an inherited predisposition to serious illness. Comprehensive pre-test education and post-test genetic counselling therefore remain essential components of responsible genomic medicine.

Another consideration involves equity of access. Advanced genomic screening should not become available only to individuals living near major academic medical centres or those able to pay privately. As sequencing costs continue declining, policymakers and healthcare systems face increasing pressure to ensure that clinically validated genomic services become more broadly accessible across diverse populations.

Building the infrastructure for the next generation of healthcare

The Mayo Clinic researchers acknowledge that the scientific capability to identify hidden genetic risk already exists. The remaining challenge lies in developing healthcare infrastructure capable of acting consistently on that knowledge.

“The study positions predictive genomic screening as both a clinical opportunity and a systems challenge. The science exists. Researchers and clinicians are still building the infrastructure to act on it consistently.”

That infrastructure extends well beyond sequencing laboratories. It includes secure digital health records capable of incorporating genomic information, decision-support systems for physicians, reimbursement models, expanded genetic counselling services, clinician education programmes and ongoing clinical research that continues refining risk prediction.

Large-scale collaboration also plays an increasingly important role.

“The work draws on expertise from across Mayo Clinic and is supported by Mayo Clinic Platform, which brings together large-scale patient data and advanced computing to enable scientists to study disease across populations.”

This multidisciplinary approach reflects the reality that predictive healthcare cannot rely upon genetics alone. It requires cooperation among molecular biologists, clinicians, bioinformaticians, epidemiologists, data scientists, ethicists and healthcare administrators.

Dyson Purifier Cool PC1

Powerfully cools you with purified air. Captures gases and 99.97% of pollutants, automatically.² For a healthier home. Connects to the MyDyson™ app.

A moonshot for human health

Perhaps the most ambitious aspect of the Precure initiative is its long-term vision. Rather than improving treatment after diagnosis, it seeks to reduce the number of people who develop advanced disease in the first place.

As Dr Lazaridis explains: “Precure is one example of a moonshot for human health at Mayo Clinic. It reflects Mayo Clinic’s commitment to move medicine beyond treatment and toward lasting wellness.”

This philosophy aligns with broader international trends in precision health, preventative medicine and population genomics. Around the world, healthcare systems increasingly recognise that preventing disease often produces better patient outcomes while reducing long-term healthcare costs associated with advanced chronic illness.

Although genomic screening cannot predict every disease, nor eliminate every health risk, it adds another powerful layer to modern preventative care. Combined with healthy lifestyle choices, vaccination, routine medical examinations and evidence-based screening programmes, genomic medicine offers an opportunity to personalise prevention in ways that were unimaginable only a generation ago.

A new era of preventative medicine

The Mayo Clinic study offers compelling evidence that preventative genomic screening has moved beyond theoretical promise into practical clinical application. Discovering that approximately one in eight apparently healthy adults carries an actionable genetic risk challenges long-held assumptions about who should receive genetic testing and when.

Equally important, the research demonstrates that successful genomic medicine depends on far more than sequencing DNA. It requires expert interpretation, compassionate genetic counselling, coordinated clinical follow-up and healthcare systems capable of integrating genomic knowledge into everyday medical practice.

Precure Genomic screening represents one of the clearest examples of this new direction. By combining whole-genome sequencing, artificial intelligence, advanced computing and multidisciplinary clinical expertise, the initiative seeks to identify disease during its earliest biological stages, when intervention has the greatest potential to preserve health.

The vision is both ambitious and increasingly attainable: a future in which medicine does not wait for symptoms to appear before taking action. Instead, healthcare becomes predictive, personalised and preventative, enabling individuals to understand their inherited risks and work with their healthcare providers to reduce them long before serious disease has the opportunity to develop.

As genomic science continues advancing and healthcare systems evolve to support its implementation, initiatives such as Precure may ultimately redefine preventative medicine for the twenty-first century, shifting the focus from treating illness to preserving lifelong health through earlier knowledge, earlier intervention and more informed clinical decision-making.